Olaparib & Durvalumab ... ASCO 2017
Grade 3/4 adverse events have included anemia (3/14, 21%), thrombocytopenia, lymphopenia, leukopenia, neutropenia, nausea, vomiting, hypertension, syncope, fatigue, UTI, and lung infection (1/14, 7% in the rest).
Seven (of 16) patients (44%) on-study >2 months have had PSA declines > 50%.
Grade 3/4 adverse events have included anemia (3/14, 21%), thrombocytopenia, lymphopenia, leukopenia, neutropenia, nausea, vomiting, hypertension, syncope, fatigue, UTI, and lung infection (1/14, 7% in the rest).
Seven (of 16) patients (44%) on-study >2 months have had PSA declines > 50%.